Skip to main content

HOPA Abstracts

Updates on Immunotherapy in Advanced Melanoma
Updates on Immunotherapy in Advanced Melanoma
By Meg Barbor, MPH
Melanoma, HOPA Abstracts, HOPA Abstracts & Highlights
TOP - May 2018, Vol 11, No 1

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Jaime Anderson, PharmD, BCOP, reviewed recent efficacy and safety data on immune checkpoint inhibitor regimens in melanoma, and discussed disease-specific characteristics that may guide treatment-planning decisions.

Read More ›
Targeting FMS-Like Tyrosine Kinase 3 in the Management of Patients with FLT3-Positive Acute Myeloid Leukemia
Targeting FMS-Like Tyrosine Kinase 3 in the Management of Patients with FLT3-Positive Acute Myeloid Leukemia
By Meg Barbor, MPH
Leukemia, HOPA Abstracts, HOPA Abstracts & Highlights
TOP - May 2018, Vol 11, No 1

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

Read More ›
The Strengths and Pitfalls of PD-L1 as a Biomarker for Immunotherapy
The Strengths and Pitfalls of PD-L1 as a Biomarker for Immunotherapy
By Meg Barbor, MPH
HOPA Abstracts, HOPA Abstracts & Highlights
TOP - May 2018, Vol 11, No 1

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Josiah Land, PharmD, BCOP, and Jacob Kettle, PharmD, BCOP, discussed the realities of using PD-L1 as a biomarker in oncology in the front- and second-line settings.

Read More ›
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
By Chase Doyle
Conference Correspondent, HOPA Abstracts, HOPA Abstracts & Highlights
TOP - August 2017, Vol 10, No 3
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer. Read More ›
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
By Chase Doyle
Conference Correspondent, HOPA Abstracts, HOPA Abstracts & Highlights
TOP - August 2017, Vol 10, No 3
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality. Read More ›
Graft-versus-Host Disease: Breakthroughs on the Horizon
By Chase Doyle
Conference Correspondent, HOPA Abstracts, HOPA Abstracts & Highlights
TOP - August 2017, Vol 10, No 3
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population. Read More ›
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
By Chase Doyle
Conference Correspondent, HOPA Abstracts, HOPA Abstracts & Highlights
TOP - August 2017, Vol 10, No 3
According to the re­sults of a recent survey of hematopoietic stem-cell transplantation (HSCT) professionals, burnout is prevalent across all HSCT disciplines, with pharmacists showing the highest rates of burnout and moral distress. Read More ›
A Conversation with Patrick J. Medina, PharmD, BCOP
A Conversation with Patrick J. Medina, PharmD, BCOP
HOPA Abstracts, HOPA Abstracts & Highlights
TOP - May 2017, Vol 10, No 2
Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa. Read More ›

Page 2 of 3